Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A4IJ
|
|||
| Former ID |
DAP000704
|
|||
| Drug Name |
Abacavir
|
|||
| Synonyms |
Trizivir; Ziagen; Abacavir [INN]; Abacavir (INN); Ziagen (TN); Ziagen (TM)(*Succinate salt*); [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; (+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; (+/-)-Abacavir; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ABC
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Approved | [1] | |
| Therapeutic Class |
Anti-HIV Agents
|
|||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H18N6O
|
|||
| Canonical SMILES |
C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO
|
|||
| InChI |
1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1
|
|||
| InChIKey |
MCGSCOLBFJQGHM-SCZZXKLOSA-N
|
|||
| CAS Number |
CAS 136470-78-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9826, 603460, 612310, 7978623, 10298786, 14775540, 14799909, 26757979, 26757980, 36885172, 46505718, 51091399, 57403623, 70504220, 76364492, 81092778, 85612588, 92729708, 103463308, 104052305, 104625144, 126654052, 128575040, 131298145, 135025044, 136345668, 137006087, 142178555, 160845918, 160964383, 162011475, 162176802, 163621096, 163686421, 163883088, 164814948, 165235811, 175267614, 175442679, 179149865, 184545024, 186014779, 196109919, 223516662, 223703089, 223704757, 223900945, 226424139, 241033176, 241383802
|
|||
| ChEBI ID |
CHEBI:421707
|
|||
| ADReCS Drug ID | BADD_D00008 ; BADD_D00009 ; BADD_D00010 | |||
| SuperDrug ATC ID |
J05AF06
|
|||
| SuperDrug CAS ID |
cas=136470785
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Abacavir Sulfate (adjusted p-values: 5.84E-04). | |||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Abacavir (marketed as Ziagen) and Abacavir-containing Medications. FDA. 2008. | |||
| REF 2 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 3 | Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.